Advaxis Inc (ADXS) - Financial and Strategic SWOT Analysis Review

November 2021 | 47 pages | ID: AAA9A2856D4EN
GlobalData

Abstracts

Advaxis Inc (ADXS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Advaxis Inc (Advaxis) is a biotechnology company that focuses on the discovery, development and commercialization of multiple cancer immunotherapies. The company develops immunotherapies based on its proprietary Lm Technology, an antigen delivery platform that activates the immune system naturally. The Lm technology uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria to stimulate cancer-fighting T cells directed against cancer antigen. Its immunotherapy candidates are intended for the treatment of neoantigen-directed therapies, prostate cancer and human papilloma virus associated cancers. The company has partnership with various biopharmaceutical companies to develop and commercialize proprietary cancer immunotherapies. Advaxis is headquartered in Princeton, New Jersey, the US.

Advaxis Inc Key Recent Developments

Sep 10,2021: Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update
Jun 14,2021: Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
Apr 12,2021: Advaxis announces $20 million registered direct offering priced at-the-market under Nasdaq Rules
Mar 23,2021: Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference
Mar 16,2021: Advaxis reports first quarter ended january 31, 2021 financial results and provides a business update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Advaxis Inc - Key Facts
Advaxis Inc - Key Employees
Advaxis Inc - Key Employee Biographies
Advaxis Inc - Major Products and Services
Advaxis Inc - History
Advaxis Inc - Company Statement
Advaxis Inc - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
Advaxis Inc - Business Description
Advaxis Inc - Corporate Strategy
Advaxis Inc - SWOT Analysis
SWOT Analysis - Overview
Advaxis Inc - Strengths
Advaxis Inc - Weaknesses
Advaxis Inc - Opportunities
Advaxis Inc - Threats
Advaxis Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Advaxis Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Sep 10, 2021: Advaxis Reports 3rd Quarter Ended July 31, 2021 Financial Results and Provides a Business Update
Jun 14, 2021: Advaxis Reports Second Quarter Ended April 30, 2021 Financial Results and Provides a Business Update
Apr 12, 2021: Advaxis announces $20 million registered direct offering priced at-the-market under Nasdaq Rules
Mar 23, 2021: Advaxis to Present Corporate Overview at the Benzinga Biotech Small Cap Conference
Mar 16, 2021: Advaxis reports first quarter ended january 31, 2021 financial results and provides a business update
Jan 25, 2021: Advaxis reports fiscal year 2020 financial results and provides a business update
Sep 10, 2020: Advaxis reports third quarter ended July 31, 2020 financial results and provides a business update
Sep 04, 2020: Advaxis announces resignation of Chief Financial Officer
Jun 11, 2020: Advaxis reports second quarter ended April 30, 2020 financial results and provides a business update
Jun 01, 2020: Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Advaxis Inc, Key Facts
Advaxis Inc, Key Employees
Advaxis Inc, Key Employee Biographies
Advaxis Inc, Major Products and Services
Advaxis Inc, History
Advaxis Inc, Key Competitors
Advaxis Inc, Ratios based on current share price
Advaxis Inc, Annual Ratios
Advaxis Inc, Annual Ratios (Cont...1)
Advaxis Inc, Interim Ratios
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Advaxis Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Advaxis Inc, Performance Chart (2016 - 2020)
Advaxis Inc, Ratio Charts
Advaxis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Advaxis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021